| Bio |
I am a Stage IV metastatic melanoma survivor, cancer free since September 2021, thanks to Relativity-047 clinical trial. I received the combination of Relatlimab, a LAG-3–blocking antibody, and Nivolumab, a PD-1–blocking antibody during the clinical trial. I stopped immunotherapy infusions beginning January 2023 because the immunotherapy related adverse effect of Fatigue was becoming debilitating.
|
